A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total

Trial Profile

A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs CVA 21 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Viralytics
  • Most Recent Events

    • 07 Jun 2016 Combined results of parent and extension study assessing the dynamics of tumor response (n=70) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 13 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 17 Mar 2016 Results from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, according to a Viralytics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top